DRAK1 Antibody - BSA Free

Western Blot: DRAK1 Antibody [NBP1-76896] - Analysis for DRAK1 using this antibody at 2 ug/ml dilution against 10 ug/lane of MOLT4 (lane 1), A431 (lane 2) and NIH-3T3 (lane 3) cell lysates.

Immunocytochemistry/Immunofluorescence: DRAK1 Antibody [NBP1-76896] - Immunocytochemistry staining of MOLT4 cells using DRAK1 antibody at 2 ug/mL.

Immunocytochemistry/ Immunofluorescence: DRAK1 Antibody - BSA Free [NBP1-76896] - Immunofluorescence of DRAK1 in Molt cells with DRAK1 antibody at 20 ug/mL.

• Reactivity: Hu
• Applications: WB, ELISA, ICC/IF
• Clonality: Polyclonal
• Host: Rabbit
• Conjugate: Unconjugated
• Format: BSA Free
• Concentration: 1 mg/ml

DRAK1 Antibody - BSA Free Summary

• Description: Novus Biologicals Rabbit DRAK1 Antibody - BSA Free (NBP1-76896) is a polyclonal antibody validated for use in WB, ELISA and ICC/IF. Anti-DRAK1 Antibody: Cited in 1 publication. All Novus Biologicals antibodies are covered by our 100% guarantee.
• Immunogen: Antibody was raised against a peptide corresponding to amino acids near the amino terminus of human DRAK1. The immunogen is located within the first 50 amino acids of DRAK1. Amino Acid Squence: EKPGSGGSSPGATSG
• Specificity: No cross responses to DRAK2, DAP or ZIP kinases.
• Isotype: IgG
• Clonality: Polyclonal
• Host: Rabbit
• Gene: STK17A
• Purity: Peptide affinity purified

Applications/Dilutions

• Dilutions:
  • ELISA 1:100-1:2000
  • Immunocytochemistry/ Immunofluorescence 2-10 ug/ml
  • Western Blot 1 ug/ml
• Application Notes: An approximately 50 kDa band can be detected in Western Blot.
• Theoretical MW: 50 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• Control Peptide:

  DRAK1 Peptide (NBP1-76896PEP)

Packaging, Storage & Formulations

• Storage: Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
• Buffer: PBS
• Preservative: 0.02% Sodium Azide
• Concentration: 1 mg/ml
• Purity: Peptide affinity purified

Alternate Names for DRAK1 Antibody - BSA Free

• DAP kinase-related apoptosis-inducing protein kinase 1
• DRAK1
• DRAK1death-associated protein kinase-related 1
• EC 2.7.11.1
• serine/threonine kinase 17a (apoptosis-inducing)
• serine/threonine kinase 17a
• serine/threonine-protein kinase 17A
• STK17A

Background

Apoptosis is mediated by death domain containing adapter molecules and a caspase family of proteases. Certain serine/threonine protein kinases, such as ASK-1 and RIP, are mediators of apoptosis. Two novel serine/threonine kinases that induce apoptosis were recently identified and designated DRAK1 and DRAK2 for DAP kinase-related apoptosis-inducing protein kinases. DRAKs contain an N-terminal kinase domain and a C-terminal regulation domain. Overexpression of DRAK1 induces apoptosis. DRAKs have high sequence homology to DAP and ZIP kinases, and they represent a novel family of serine/threonine kinases, which mediates apoptosis through their catalytic activities. DRAK1 is located in nucleus and the messenger RNA was ubiquitously expressed in human tissues.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for DRAK1 Antibody (NBP1-76896)(1)

Publication using NBP1-76896

• Mao P, Hever MP, Niemaszyk LM et al. Serine/threonine kinase 17A is a novel p53 target gene and modulator of cisplatin toxicity and reactive oxygen species in testicular cancer cells. J Biol Chem. 2011-06-03 [PMID: 21489989] (WB, Human)
  
  Details:
  DRAk1 (IMG-157-1). WB: Human embryonal carcinoma (NT2/D1) cell line, Fig 5.

Bioinformatics

• Gene Symbol: STK17A
• Uniprot:
  • Q9UEE5()